Table 2. Aliskiren/amlodipine combination therapy versus aliskiren monotherapy on adverse events.

Category	RR	95% CI	p-value
Any AE	1.11	0.80–1.54	0.53
Dicontinuation due to AE	1.09	0.79–1.49	0.62
Any SAE	0.95	0.45–2.04	0.90
Peripheral edema	1.60	1.22–2.12	0.0008
Nasopharyngitis	1.86	0.47–7.35	0.38
Dizziness	1.39	0.71–2.74	0.34
Headache	0.37	0.12–1.17	0.09
Hyperkalaemia	0.64	0.26–1.54	0.32
Hypokalaemia	1.18	0.39–3.55	0.77

Abbreviations: RR, relative risk; CI, confidence interval; AEs, adverse events; SAEs, serious adverse events.